Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence

Oncogene

Volumn 27, Issue 56, 2008, Pages 7070-7082

  Leikam, C ^a   Hufnagel, A ^a   Schartl, M ^a   Meierjohann, S ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Melanocyte; Melanoma; N RAS; Oncogene; ROS; Senescence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MELANOMA RECEPTOR KINASE; PROTEIN P53; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FUSION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; GENE ACTIVATION; GIANT CELL; MELANOCYTE; MOUSE; NONHUMAN; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; SENESCENCE;

CELL AGING; CELL PROLIFERATION; DNA DAMAGE; DOXYCYCLINE; HUMANS; MELANOCYTES; NEOPLASMS; NEVUS; ONCOGENES; OXYGEN; PHENOTYPE; REACTIVE OXYGEN SPECIES; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149229247     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.323     Document Type: Article

References (70)

1. Aguirre AJ, Bardeesv N, Sinha M, Lopez L, Tuveson DA, Horner J et al. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126.
2. Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I et al. (2005). P53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res 3: 627-634.
3. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. (1997). Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184.
4. Bardeesy N, Kim M, Xu J, Kim RS, Shen Q, Bosenberg MW et al. (2005). Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 25: 4176-4188.
5. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633-637.
6. Bennett DC. (2003). Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22: 3063-3069.
7. Bennett DC, Cooper PJ, Dexter TJ, Devlin LM, Haesman J, Nester B. (1989). Cloned mouse melanocyte lines carrying the germline mutations albino and brown: complementation in culture. Development 105: 379-385.
8. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. (2002). Deconstructing PML-induced premature senescence. EMBO J 1: 3358-3369.
9. Blagosklonny M. (2003). Cell senescence and hypermitogenic arrest. EMBO Rep 4: 358-362.
10. Chang DL, Qui W, Ying H, Zhang Y, Chen CY, Xiao ZX. (2007). ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene 26: 4627-4634.
11. Chao C, Hergenhahn M, Kaeser MD, Wu Z, Saito S, Iggo R et al. (2003). Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 248: 41028-41033.
12. Chen CR, Wang W, Rogoff HA, Li X, Li CJ. (2005). Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation is a strategy against cancer. Cancer Res 65: 6017-6021.
13. Chin L. (2003). The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3: 559-570.
14. Collado M, Serrano M. (2006). The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472-476.
15. Curtin JA, Busam K, Pinkel D, Bastian BC. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346.
16. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
17. Debidda M, Williams DA, Zheng Y. (2006). Rac1 GTPase regulates cell genomic stability and senescence. J Biol Chem 281: 38519-38528.
18. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8: 1053-1063.
19. Dumaz N, Meek DW. (1999). Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18: 7002-7010.
20. Finkel T. (2006). Intracellular redox regulation by the family of small GTPases. Antioxid Redox Signal 8: 1857-1863.
21. Geissinger E, Weisser C, Fischer P, Schartl M. (2002). Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 62: 4820-4828.
22. Goding CR. (2000). Melanocyte development and malignant melanoma. Forum (Genova) 10: 176-187.
23. Gorla GR, Malhi H, Gupta S. (2001). Polyploidy associated with oxidative injury attenuates proliferative potential of cells. J Cell Sci 114: 2943-2951.
24. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek Z et al. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95: 496-505.
25. Gray-Schopfer VC, da Rocha Dias S, Marais R. (2005). The role of B-Raf in melanoma. Cancer Metastasis Rev 24: 165-183.
26. Ha L, Ichikawa T, Anyer M, Dickins R, Lowe S, Sharpless NE et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 104: 10968-10973.
27. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. (2006). Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12: 2301s-2307s.
28. Hayashi C, Rittling S, Hayata T, Amagasa T, Denhardt D, Ezura Y et al. (2007). Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 101: 979-986.
29. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. (2005). Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65: 4861-4869.
30. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER et al. (1997). Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652.
31. Itahana K, Dimri GP, Hara E, Itahana Y, Zou Y, Desprez PY et al. (2002). A role for p53 in maintaining and establishing the quiescence growth arrest in human cells. J Biol Chem 277: 18206-18214.
32. Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A et al. (2000). Evidence for a telomere-independent 'clock' limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol Cell Biol 20: 5690-5699.
33. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L et al. (1996). Oncogenic RAS activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16: 3923-3933.
34. Kopnin PB, Agapova LS, Kopnin BP, Chumakov PM. (2007). Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res 67: 4671-4678.
35. Krueger C, Danke C, Pfleiderer K, Schuh W, Jäck HM, Lochner S et al. (2006). A gene regulation system with four distinct expression levels. J Gene Med 8: 1037-1047.
36. Kurata S. (2000). Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. J Biol Chem 275: 23413-23416.
37. Lachat Y, Diserens AC, Nozaki M, Kobayashi H, Hamou MF, Godard S et al. (2004). INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)- dependent ERK activation in mouse astrocytes and glioma. Oncogene 23: 6854-6863.
38. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. (1998). Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273: 33048-33053.
39. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T et al. (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274: 7936-7940.
40. Leopold JG, Richards DB. (1967). Cellular blue neavi. J Pathol Bacteriol 94: 247-255.
41. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. (2001). Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20: 8125-8135.
42. Liu X, Miller CW, Koeffler PH, Berk AJ. (1993). The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 13: 3291-3300.
43. Mallette FA, Gaumont-Leclerk MF, Ferbeyre G. (2007). The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21: 43-48.
44. Malumbres M, Pérez De Castro I, Hernández MI, Jiménez M, Corral T, Pellicer A. (2000). Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15 (INK4b). Mol Cell Biol 20: 2915-2925.
45. Meierjohann S, Schartl M. (2006). From Mendelian to molecular genetics: the Xiphophorus melanoma model. Trends Genet 22: 654-661.
46. Meierjohann S, Wende E, Kraiss A, Wellbrock C, Schartl M. (2006). The oncogenic epidermal growth factor receptor variant Xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. Cancer Res 66: 3145-3152.
47. Michaloglou C, Vredeveld LC, Soengas MS, Denovelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 636-637.
48. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S et al. (2006). STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Investig Dermatol 126: 2272-2280.
49. Natali PG, Nicotra MR, Di Renzo MF, Prat M, Bigotti A, Cavaliere R et al. (1993). Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumor progression. Br J Cancer 68: 746-750.
50. Nuciforo PG, Luise C, Capra M, Pelosi G, di Fagagna FD. (2007). Complex engagement of DNA-damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 28: 2082-2088.
51. Passos JF, von Zglinicki T. (2006). Oxygen free redicals in cell senescence: are they signal transducers? Free Rad Res 40: 1277-1283.
52. Pfaffl MW, Horgan GW, Dempfle L. (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
53. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C et al. (2008). Osteopontin as a molecular prognostic marker for melanoma. Cancer 112: 144-150.
54. Rincheval V, Renaud F, Lemaire C, Godefroy N, Trotot P, Boulo V et al. (2002). Bcl-2 can promote p53-dependent senescence versus apoptosis without affecting the G1/S transition. Biochem Biophys Res Commun 298: 282-288.
55. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9: 483-485.
56. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759.
57. Savchenko I. (1988). Endomitosis in pigmented neoplasms of human skin. TSitologiia i Genetika 22: 20-24.
58. Sewing A, Wiseman B, Lloyd AC, Land H. (1997). High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17: 5588-5597.
59. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ et al. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
60. Spyridopoulos I, Isner JM, Losordo DW. (2002). Oncogenic ras induces premature senescence in endothelial cells: role of p21 (Cip1/ Waf1). Basic Res Cardiol 97: 117-124.
61. Straume O, Sviland L, Akslen LA. (2000). Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6: 1845-1853.
62. Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, Easty DJ et al. (2002). p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 94: 446-454.
63. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K et al. (2006). Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8: 1291-1297.
64. Vigneron A, Roninson IB, Gamelin E, Coqueret O. (2005). Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking induction of p21 waf1. Cancer Res 65: 8927-8935.
65. Wellbrock C, Geissinger E, Gómez A, Fischer P, Friedrich K, Schartl M. (1998). Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. Oncogene 16: 3047-3056.
66. Wellbrock C, Schartl M. (1999). Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. Eur J Biochem 260: 275-283.
67. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M. (2002). Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 277: 6443-6454.
68. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS et al. (2005). STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 15: 1629-1639.
69. Wittbrodt J, Lammers R, Malitschek B, Ullrich A, Schartl M. (1992). The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. EMBO J 11: 4239-4246.
70. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611.